Welcome to the 3rd Molecular Glue Drug Development Summit
Pioneering Rationally Designed Molecular Glue Degraders for Clinical Application
Molecular glue development continues to thrive, offering exciting opportunities to target previously undruggable proteins and treat a wide range of diseases. 2024 has seen a multitude of collaborations, with Takeda and Degron Therapeutics entering a deal worth $1.2 billion.
The 3rd Molecular Glue Drug Development Summit returns as the only industry-dedicated forum bringing together 90+ experts as they showcase the latest advancements and breakthroughs in molecular glue drug development through discussions and data-driven case studies on screening tools, novel mechanisms of actions of proximity-based degrading and non-degrading molecular glues and lead optimization strategies, to streamline discovery and development of safe and effective glues.
2025 World-Class Speaker Faculty Includes:
Rana Quraishi
CEO - Isoprene Pharmaceuticals
Yao Wang
Chief Medical Officer - Kangpu Biopharmaceuticals
Matthias Brand
Chief Technology Officer - Proxygen GmbH
Rick Ewing
Vice President & Head of Chemistry - Rapafusyn Pharmaceuticals
Matthew Hayward
Vice President of Drug Discovery - Magnet Biomedicine
Felix Hausch
Professor - Technical University of Darmstadt